The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 9, 2010, Pages 1272-1281

  Lin, Yu Feng ^a,b   Lairson, David R ^b   Chan, Wenyaw ^b   Du, Xianglin L ^b   Leung, Kathryn S ^a   Kennedy Nasser, Alana A ^a   Martinez, Caridad A ^a   Gottschalk, Stephen M ^a   Bollard, Catherine M ^a   Heslop, Helen E ^a   Brenner, Malcolm K ^a   Krance, Robert A ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Children; Long term follow up; Treatment success

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; FOLLOW UP; GRAFT RECIPIENT; HEALTH CARE COST; HUMAN; INFANT; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 77955511215     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.03.016     Document Type: Article

References (36)

1. Schmitz N., Linch D.C., Dreger P., et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357.
2. To L.B., Roberts M.M., Haylock D.N., et al. Comparison of heamatological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992, 9:277-284.
3. Roberts M.M., To L.B., Gillis D., et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993, 12:469-475.
4. Nademanee A., Schmidt G.M., Parker P., et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate and prednisone. Blood 1995, 86:1228-1234.
5. Nash R.A., Piñeiro L.A., Storb R., et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996, 88:3634-3641.
6. Anasetti C., Etzioni R., Petersdorf E.W., et al. Marrow transplantation from unrelated volunteer donors. Annu Rev Med 1995, 46:169-179.
7. Goodrich J.M., Mori M., Gleaves C.A., et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Eng J Med 1991, 325:1601-1607.
8. Schmidt G.M., Horak D.A., Niland J.C., et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bond marrow transplantation. N Eng J Med 1991, 324:1005-1011.
9. Rooney C.M., Smith C.A., Ng C.Y., et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995, 345:9-13.
10. Heslop H.E., Ng C.Y., Li C., et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996, 2:551-555.
11. Handgretinger R., Klingebiel T., Lang P., et al. Megadose transplantation of purified peripheral blood CD 34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001, 27:777-783.
12. Anderlini P., Rizzo J.D., Nugent M.L., et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) database. Bone Marrow Transplant 2001, 27:689-692.
13. Körbling M., Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood 2001, 98:2900-2908.
14. Barker J.N., Wagner J.E. Umbilical cord blood transplantation: current state of the art. Curr Opin Oncol 2002, 14:160-164.
15. Gluckman E., Locatelli F. Umbilical cord blood transplant. Curr Opin Hematol 2000, 7:353-357.
16. Couban S., Dranitsaris G., Andreou P., et al. Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Bone Marrow Transplant 1998, 22:1199-1205.
17. Bennett C., Waters T., Stinson T., et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999, 24:555-560.
18. van Agthoven M., Groot M.T., Verdonck L.F., et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantations in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002, 30:243-251.
19. Majhail N.S., Mothukuri J.M., Brunstein C.G., et al. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttranplantation complications. Biol Blood Marrow Transplant 2009, 15:564-573.
20. Costa V., McGregor M., Laneuville P., et al. The cost-effectiveness of stem cell transplantations from unrelated donors in adult patients with acute leukemia. Value Health 2007, 10:247-255.
21. Hongeng S., Krance R.A., Bowen L.C., et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukemia. Lancet 1997, 350:767-771.
22. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974, 18:295-304.
23. Bureau of Labor Statistics. The Consumer Price Index (CPI), 2008. Available from: Accessed January 12, 2009. http://www.bls.gov/cpi/.
24. Weisberg S. Outliers and influence. Applied Linear Regression 2005, Wiley, New York. S. Weisberg (Ed.).
25. Mooney C.Z., Duval R.D. Conclusion. Bootstrapping: A Nonparametric Approach to Statistical Inference 1993, Sage, Thousand Oaks, CA. C.Z. Mooney, R.D. Duval (Eds.).
26. Critchfield G.C., Willard K.E., Connelly D.P. Probability sensitivity analysis methods for general decision models. Comput Biomed Res 1986, 19:254-265.
27. Doubilet P., Begg C.B., Weinstein M.C., et al. Probability sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985, 5:157-177.
28. Manning W.G., Fryback D.G., Weinstein M.C. Reflecting uncertainty in cost-effectiveness analysis. Cost-Effectiveness in Health and Medicine 1996, Oxford University Press, New York. M.R. Gold, J.E. Siegel, L.B. Russel (Eds.).
29. Lee S.J., Anasetti C., Kuntz K.M., et al. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood 1998, 92:4047-4052.
30. Uyl-de Groot C.A., Hagenbeek A., Verdonck L.F., et al. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 1995, 16:463-470.
31. Welch H.G., Larson E.B. Cost-effectiveness of bone marrow transplantation in acute non-lymphocytic leukemia. N Eng J Med 1989, 321:807-812.
32. Messori A., Bonistalli L., Costantini M., et al. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997, 19:275-281.
33. Barr R., Furlong W., Henwood J., et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 1996, 14:1413-1420.
34. Beard M.E., Inder A.B., Allen J.R., et al. The costs and benefits of bone marrow transplantation. N Z Med J 1991, 104:303-305.
35. Kouroukis C.T., O'Brien B.J., Benger A., et al. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma. Leuk Lymphoma 2003, 44:29-37.
36. Madero L., González Vincent M., Ramirez M., et al. Clinical and economic comparison of allogeneic peripheral blood progenitor cell and bone marrow transplantation for acute lymphoblastic leukemia in children. Bone Marrow Transplant 2000, 26:269-273.